1. Effects of Long-acting Release Octreotide on Glucose Homeostasis in Acromegaly Patients after Trans-Sphenoidal Surgery
- Author
-
S.-H. Lin, H.-S. Chen, H.-D. Lin, Jap Ts, T.-E. Wu, S.-H. Lee, and L.-C. Hsiao
- Subjects
Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Clinical Biochemistry ,Octreotide ,Biochemistry ,Young Adult ,Endocrinology ,Internal medicine ,Diabetes mellitus ,Sphenoid Bone ,Acromegaly ,medicine ,Homeostasis ,Humans ,Insulin ,Glucose homeostasis ,Young adult ,Prospective cohort study ,Aged ,Glucose tolerance test ,medicine.diagnostic_test ,business.industry ,Biochemistry (medical) ,General Medicine ,Glucose Tolerance Test ,Middle Aged ,medicine.disease ,Surgery ,Female ,business ,medicine.drug - Abstract
The present study was aimed to investigate glucose homeostasis and insulin secretion in acromegalic patients during octreotide-long acting release (LAR) therapy and designed as an observational prospective study. 18 acromegalic patients who had undergone trans-sphenoidal surgery with active disease were included. All patients were treated with octreotide-LAR injection for 1 year. These patients received oral glucose tolerance test (OGTT) before, 21 days after, and 1 year after octreotide-LAR treatment. Primary outcomes were changes in glucose levels and insulin secretion during an OGTT. We also determined the differences between subjects with normalized and uncontrolled IGF-1 levels. Of the 18 patients treated with octreotide-LAR for 1 year, 89% achieved fasting GH levels
- Published
- 2011